ClinicalTrials.gg
RecruitingNCT06247397HILOTUpdated Nov 19, 2026

Effect of HIgh-flow Therapy in Long-term Oxygen Therapy

An interventional study of Added high-flow oxygen therapy and Standard care in Chronic Obstructive Pulmonary Disease Severe, Interstitial Lung Disease and Chronic Respiratory Failure With Hypoxia, sponsored by Skane University Hospital. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Skane University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Nov 19, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).

Read the detailed description

This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.

The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease Severe
  • Interstitial Lung Disease
  • Chronic Respiratory Failure With Hypoxia
03

In context

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.

This study's planned enrollment of 310 is above the median of 60 across 386 interventional studies indexed under Lung Diseases, Interstitial.

Browse Lung Diseases, Interstitial studies →

Lead sponsor

Skane University Hospital is the lead sponsor of 73 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40 years or older
  • Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
  • or ILD as main underlying reason for LTOT
  • Oxygen concentrator as stationary oxygen source in the home including night-time
  • (BMI) \< 35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Current or previous treatment with home HFOT
  • Current treatment with home mechanical ventilation
  • Current treatment with home CPAP
  • Hospitalized during the last 2 weeks
  • Current smoking or contact with flames
  • Self-reported average use of the LTOT \< 15h per day (24 hours)
  • PaCO2 (breathing air at rest) > 8 kPa
  • Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
  • Inability to participate in the study procedures (as judged by the staff)
  • Not eligible for continuing LTOT due to other reason (as judged by the staff)
  • Expected survival less than 3 months (as judged by the staff)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    High-flow oxygen therapy

    Intervention arm

    Device: Added high-flow oxygen therapy

  • Active comparator
    Low-flow oxygen therapy

    Comparison arm

    Other: Standard care

Interventions

  • DeviceAdded high-flow oxygen therapy

    Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.

  • OtherStandard care

    Standard care with low-flow oxygen therapy in accordance with clinical routine.

06

What researchers measure

Primary outcomes

  1. Time to first hospitalization or death from all causes

    Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data)

    Time frame: 1 year

Secondary outcomes

  1. Time to first all-cause hospitalization or all-cause death

    Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data)

    Time frame: 1 year

  2. Rate of hospitalizations or death from all causes

    Rate of hospitalizations or death from all causes assessed using nationwide registry data

    Time frame: 1 year

  3. Hospitalization rate from all causes

    Hospitalization rate from all causes assessed using nationwide registry data

    Time frame: 1 year

  4. Hospitalization rate from respiratory disease

    Hospitalization rate from respiratory disease assessed using nationwide registry data

    Time frame: 1 year

  5. Number of hospitalized days

    Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data

    Time frame: 1 year

  6. Hospitalization rate from cardiovascular disease

    Hospitalization rate from cardiovascular disease assessed using nationwide registry data

    Time frame: 1 year

  7. Number of admissions to intensive care unit (ICU)

    Number of admissions to ICU assessed using nationwide registry data

    Time frame: 1 year

  8. Number of days in ICU

    Number of days in ICU assessed using nationwide registry data

    Time frame: 1 year

  9. Mortality rate from all causes

    The mortality rate from all causes assessed using nationwide registry data

    Time frame: 1 year

  10. Mortality rate from respiratory disease

    The mortality rate from respiratory disease assessed using nationwide registry data

    Time frame: 1 year

  11. Mortality rate from cardiovascular disease

    The mortality rate from cardiovascular disease assessed using nationwide registry data

    Time frame: 1 year

  12. Time to first exacerbation

    Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data

    Time frame: 1 year

  13. Number of exacerbations

    Number of exacerbations of all severity assessed using self-reported and registry data

    Time frame: 1 year

  14. Incidence of cardiovascular disease

    Incidence of cardiovascular disease assessed using nationwide registry data

    Time frame: 1 year

  15. Need for home mechanical ventilation

    Need for starting home mechanical ventilation assessed using nationwide registry data

    Time frame: 1 year

  16. Rate of withdrawal of long-term oxygen therapy

    Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data

    Time frame: 1 year

  17. Adverse events

    Self-reported adverse events since study start assessed using a postal questionnaire.

    Time frame: 3 and 12 months

  18. Primary care utilization

    Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire.

    Time frame: 1 year

  19. Health-related quality of life

    Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire.

    Time frame: 3 and 12 months

  20. Health status

    Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire.

    Time frame: 3 and 12 months

  21. Breathlessness at exertion

    Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire.

    Time frame: 3 and 12 months

  22. Breathlessness

    Self-reported breathlessness assessed using the Dyspnea-12 questionnaire.

    Time frame: 3 and 12 months

  23. Sleep quality

    Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire.

    Time frame: 3 and 12 months

  24. Physical activity

    Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire.

    Time frame: 3 and 12 months

  25. Change in health status

    Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale.

    Time frame: 3 and 12 months

  26. Nasal symptoms

    Self-reported nasal symptoms assessed using the modified Björklund questionnaire.

    Time frame: 3 and 12 months

Other outcomes

  1. Patient preference for continuing the treatment

    Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire.

    Time frame: 3 and 12 months

07

Study locations

2 of 2 sites recruiting
  • Research Unit, Blekinge University of Technology
    Karlskrona, Blekinge County 37185, Sweden
    Recruiting
  • Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
    Örebro, 70185, Sweden
    Recruiting
    • Josefin Sundh, MD, PhD · Contact
08

References and documents

Publications

  • Sundh J, Ljunggren M, Palm A, Lindberg E, Lavergne F, Weinreich UM, Ahmadi Z, Ekstrom M; HILOT Collaboration Group. Effect of HIgh-Flow Therapy in Long-Term Oxygen Therapy (HILOT): study protocol for a multicentre, registry-based, randomised clinical trial. Trials. 2026 Feb 4;27(1):177. doi: 10.1186/s13063-026-09488-8. PubMed 41634827 ↗

Individual participant data

Plan to share: No — IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2028, 54 months after the start.

Of 114 non-industry interventional studies with no phase under Lung Diseases, Interstitial, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 54 months is above that.

Counting every sponsor, half of 119 studies reached it within 27 months; a quarter within 14 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2027 → Dec 2028 and completion Dec 2028 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2024
First posted
Feb 7, 2024
StartActual
Jun 10, 2024
Primary completionEst.
Dec 2028was Dec 2027
CompletionEst.
Dec 2029was Dec 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Research Unit, Blekinge University of Technology · Karlskrona, Sweden
Show 1 removed
  • Research Unit, Blekinge University of Technology · Karlskrona, Sweden
Nov 19, 2026
Primary completion
Dec 2027→Dec 2028
Nov 19, 2026
Study completion
Dec 2028→Dec 2029
Nov 19, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41634827 ↗
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41634827 ↗
    1 site added, 1 site removed
    Show site
    • Research Unit, Blekinge University of Technology · Karlskrona, Sweden
    Show 1 removed
    • Research Unit, Blekinge University of Technology · Karlskrona, Sweden
    Primary completion Dec 2027→Dec 2028
    Study completion Dec 2028→Dec 2029
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06247397
Lead sponsor
Skane University Hospital
Collaborators
Uppsala University Hospital, Region Stockholm, Region Örebro County, Blekinge County Council Hospital, Blekinge Institute of Technology, Lund University, Region Östergötland, Vastra Gotaland Region, Region Västerbotten, Landstinget i Värmland, ResMed, Swedish Heart Lung Foundation, The Swedish Research Council
Responsible party
Magnus Ekström (Associate Professor, Senior Lecturer, Skane University Hospital) — Principal investigator
First posted
Feb 7, 2024
Start date
Jun 10, 2024
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Magnus Ekström, MD, PhD
Contact
magnus.ekstrom@med.lu.se
0455731000 ext. +46
Magnus Ekström, MD, PhD
principal investigator · Skane University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion